Evidence map›Paper›PMID 33889301›Full record

ArticleOncotarget2021

Urine protein biomarkers of bladder cancer arising from 16-plex antibody-based screens.

Kamala Vanarsa, Shereen Enan, Pooja Patel, Briony Strachan, Anto Sam Crosslee Louis Sam Titus, Aphrihl Dennis, Yair Lotan, Chandra Mohan

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Kamala VanarsaDepartment Biomedical Engineering, University of Houston, Houston, TX, USA.
Shereen EnanDepartment Biomedical Engineering, University of Houston, Houston, TX, USA.
Pooja PatelDepartment Biomedical Engineering, University of Houston, Houston, TX, USA.
Briony StrachanDepartment Biomedical Engineering, University of Houston, Houston, TX, USA.
Anto Sam Crosslee Louis Sam TitusDepartment Biomedical Engineering, University of Houston, Houston, TX, USA.
Aphrihl DennisDepartment of Urology, UT Southwestern Medical Center, Dallas, TX, USA.
Yair LotanDepartment of Urology, UT Southwestern Medical Center, Dallas, TX, USA.
Chandra MohanDepartment Biomedical Engineering, University of Houston, Houston, TX, USA.
University of Houston · USThe University of Texas Southwestern Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe purpose of this study is to identify novel urine protein biomarkers of bladder cancer using a Luminex based screening platform. MATERIALS AND

methodsThe current study examines urine samples from 66 subjects, comprised of 31 Urology clinic controls and 35 bladder cancer patients, using a Luminex based screening platform. ELISA validation was carried out for the top 4 prospective urine biomarkers using an independent cohort of 20 Urology clinic controls and 60 bladder cancer (BC) subjects.

resultsOf the 16 proteins screened by Luminex, 10 showed significant elevation in BC compared to the controls. Eight of these urine proteins were able to differentiate BC from control urine with ROC AUC values exceeding 0.70 at

conclusionsThese findings suggest that urine IL-1α, IL-1ra and IL-8 are useful indicators of bladder cancer. Urine IL-8 not only distinguishes bladder cancer from controls, it also discriminates high grade from low grade disease, and the successive clinical stages of bladder cancer. While supportive of previous reports, these findings warrant further analysis in prospective cohorts.

Indexed as

inflammationinterleukinsproteomicstargeted screensurothelial

Identifiers

PMID33889301
PMCPMC8057279
OpenAlexW3154739466

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.